FIELD: medicine.
SUBSTANCE: invention refers to immunotherapeutic agents containing cytoderm fragments of virulent strain of complex Mycobacterium tuberculosis. Invention describes method of immunotherapeutic agent production as follows. Microbacteria cells are cultivated, homogenised with nonionic surfactant to produce end product as homogenate of nonfragmented cells, cytoderm fragments and cellular solubiliser. Method can additionally include centrifugation of homogenate to separate, irrigate cytoderm fragments and to lyophilise purified end product. Invention also refers to pharmaceutical preparations containing immunotherapeutic agents applied to produce medical product for combined treatment of tuberculosis coupled with the other medical products.
EFFECT: allows for higher efficiency of used medical products concerning immune response induction against microbacteria out of active metabolism thereby reducing risk of resistance to medical products.
34 cl, 6 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| IMMUNOTHERAPEUTIC AGENT FOR PRIMARY PREVENTION OF TUBERCULOSIS | 2009 |
|
RU2544125C2 |
| LIPOSOME FORMULATION SUITABLE FOR TREATING OR PREVENTING TUBERCULOSIS | 2012 |
|
RU2648842C2 |
| PREVENTIVE ANTI-TUBERCULOSIS VACCINE | 2007 |
|
RU2526910C2 |
| COMPOSITIONS AND METHODS FOR TREATING ACTIVE MYCOBACTERIUM TUBERCULOSIS INFECTION | 2013 |
|
RU2659149C2 |
| ANTITUBERCULOSIS REMEDY | 2017 |
|
RU2756208C2 |
| COFORMULATED ANTITUBERCULOUS DRUG | 2009 |
|
RU2430724C2 |
| USE OF NANOPHOSPHOLIPID COMPOSITION OF RIFAMPICINE TOGETHER WITH PROTIONAMIDE OR ITS NANOPHOSPHOLIPID FORM IN TREATMENT OF TUBERCULOSIS | 2014 |
|
RU2595881C2 |
| NEW EFFECTIVE THERAPEUTIC TARGET FOR TREATING TUBERCULOSIS | 2008 |
|
RU2474621C2 |
| INACTIVATED MYCOBACTERIA FOR ORAL USE IN THE PREVENTION OF TUBERCULOSIS | 2013 |
|
RU2657753C2 |
| ORAL SOLID PREPARATION OF COMPOUND ANTITUBERCULOSIS DRUG AND PREPARATION METHOD THEREOF | 2012 |
|
RU2605388C2 |
